Navigation Links
Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
Date:6/12/2008

ents in this news release related to the possible effectiveness of the company's PHOENIX delivery system or other technologies and the effect of such system or technology on the company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the company to ship product on a timely basis; the company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; restrictions contained in our convertible debt obligations requiring the issuance of shares rather than repayment in cash; and the company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the company's other recent SEC filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press releas
'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
2. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
3. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
4. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
7. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
10. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/15/2014)... (PRWEB) December 15, 2014 A recent ... United States women as impacting skin health and beauty ... C’s of skin care.” Water and health advocate and ... a recent article describing the survey and the Four ... item in every category discussed would benefit from paying ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ... on a new study providing evidence on the impact ... of children. , Sufficient enough evidence already exists showing ... or juice drinks, with the onset of tooth decay. ... drinks listed as 100% fruit juice, meaning it is ...
(Date:12/15/2014)... December 15, 2014 OutMarket , ... released “ Social Media Cheat Sheets ,” a guide ... that drives results on the top ten social media ... It helps drive awareness, engagement, and customer service. It ... to make an impact on new networks and weather ...
(Date:12/15/2014)... (HealthDay News) -- Expert pilots process visual information more ... make better decisions during landings, a new study shows. ... for pilots to master, and 36 percent of all ... during final approach and landing. Researchers monitored the ... experienced pilots while they were at the controls of ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory ... and South America, Europe, the Middle East, Asia and ... its 2015 Medical Device Industry Survey. Each year, Emergo ... and market trends as well as regulatory and operational ... including:, , Overall prospects for medical ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... -- Home Health Equipment business sold in two ... debt reduction, additional working capital to fund DailyMed(TM) ... Amex: KAD ), a leading provider ... under the Arcadia HealthCare(SM) brand, today announced the ...
... TSX: COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ ... today announced that the waiting period under the Hart-Scott-Rodino ... & Co., Inc. and a Merck affiliate for development ... treatment of atrial fibrillation, has expired, and the agreement ...
... Inc., headquartered in Orlando, FL, a leading provider ... predictive analytics, announced today that its solutions are ... the Centers for Medicare & Medicaid Services mandate, ... a medication therapy management (MTM) program.MEDai,s solutions ...
... -- Cylene Pharmaceuticals, Inc., announced today that ... their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO ... William G. Rice, Ph.D., Cylene,s president and CEO, will ... CX-4945, the Company,s oral protein kinase inhibitor currently in ...
... Donnica Moore Translates Sleep Facts from FictionWASHINGTON, May 19 ... today that, together with sanofi-aventis U.S., it has joined ... to debunk common myths and misperceptions about sleep. The ... Smart , which helps educate Americans about the importance ...
... social network the chance to meet one another and ... site, topics of interest to be discussed & members, ... www.FertilityTies.com ), the most comprehensive social network ... that combines expertise of accredited MDs, will bridge the ...
Cached Medicine News:Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 2Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 3Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 4Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:MEDai Helps Medicare Part D Sponsors Adhere to CMS Medication Therapy Management Initiative 2Health News:Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference 2Health News:Video: NSF Enlists Renowned Women's Health Expert to 'School' America on Sleeping Smart 2Health News:Video: NSF Enlists Renowned Women's Health Expert to 'School' America on Sleeping Smart 3Health News:Video: NSF Enlists Renowned Women's Health Expert to 'School' America on Sleeping Smart 4Health News:Video: NSF Enlists Renowned Women's Health Expert to 'School' America on Sleeping Smart 5Health News:FertilityTies.com Convention Open to the Public, June 6, 1-5 PM at The Hilton New York Hotel, MDs to Lead Discussion on Timely Fertility Topics 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: